Novartis on Thursday announced that it plans to file for a label expansion for its radioligand therapy Pluvicto (lutetium-177 vipivotide tetraxetan) later this year, proposing to use the prostate cancer treatment in patients who have not yet undergone chemotherapy.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,